Embla Medical (EMBLA) Investor presentation summary

Emerging markets overview and growth potential

• Emerging markets account for over 80% of new amputee volume globally but only about 10% of current sales, indicating significant growth potential.

• Recent sales growth in these regions is driven by countries like Brazil, Mexico, India, South Africa, and Ukraine.

• The addressable market in emerging regions is estimated at $400–500 million for 2024/25, with annual growth rates of 10–12%.

• Six key markets represent around 90% of the volume opportunity.

• A tailored approach is required due to varying market maturity and reimbursement structures.

Strategic approach and challenges

• Less than 20% of new amputees in emerging markets are fitted with prostheses, with some regions as low as 5%.

• Key challenges include limited healthcare access, low reimbursement, infrastructure shortages, and low awareness.

• Strategy focuses on optimizing operations, expanding distribution and clinics, and pioneering new go-to-market models for private pay.

• Portfolio expansion into the value segment and acquisitions like Streifeneder support tailored offerings.

Market-specific initiatives: India and Ukraine

• India has 8–9 million amputees, with only 5–15% fitted with prostheses; most are of productive age and infrastructure is limited.

• India is targeted as a pilot for private pay clinics, focusing on access, awareness, and affordability, with plans to scale successful models.

• Ukraine has seen a sharp rise in young amputees due to war, with 50,000–100,000 new cases since 2022 and a high need for advanced bionics.

• New clinic in Kyiv and partnerships aim to support up to 1,000 amputees, with efforts to strengthen local presence and secure funding.

• Delayed fittings and limited clinical capacity have created a substantial backlog, emphasizing the need for infrastructure and recurring care.